SRINAGAR: In a significant move to revolutionise clinical research in India, Novo Nordisk India Pvt Ltd and Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, have signed a Memorandum of Understanding (MoU) to collaborate on clinical trials aimed at improving patient outcomes. This partnership marks a major milestone as both organisations combine their expertise to innovate and advance the healthcare landscape in the region.
The MoU, valid for three years, will focus on groundbreaking research in areas such as cardiology, obesity, nephrology, and rare diseases. As part of the agreement, Novo Nordisk will provide resources, training, and equipment to enhance SKIMS’ research capacity. SKIMS, in turn, will facilitate the clinical trial approval process and ensure patient safety and participation.
“This partnership underscores our commitment to redefining clinical research in India,” Vikrant Shrotriya, Managing Director and Corporate Vice President of Novo Nordisk India, was quoted as having signed at the MoU signing event. “By combining Novo Nordisk’s global expertise with SKIMS’ exceptional medical infrastructure, we aim to deliver life-changing healthcare solutions, particularly to underserved communities.”
“This initiative is a significant step towards enhancing clinical research standards in the region,” Dr Mohammed Ashraf Ganie, Director of SKIMS, emphasised the importance of the collaboration. “It will not only drive medical advancements but also ensure world-class healthcare access for the people of Jammu and Kashmir.”
The collaboration will focus on bridging gaps in access to advanced medicines and pioneering new therapeutic interventions. By leveraging the combined strengths of both parties, the MoU sets the stage for future innovations in clinical trials, ultimately aiming to bring life-saving treatments to a larger patient population.
